Heterogeneity of Minimal/Measurable Residual Disease (MRD) Practices in Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in the United States

Juliana E. Hidalgo-Lopez,Gail J. Roboz,Brent Wood,Michael Borowitz,Elias J. Jabbour,Kelly Velasco,Ehab Elkhouly,Babatunde Adedokun,Faraz Zaman,Karim Iskander,Aaron C. Logan

Blood（2021）

引用 0|浏览11

暂无评分

摘要

Background: MRD testing in BCP-ALL is critical for appropriate patient management, but little is known regarding sample acquisition and testing heterogeneity across clinical practice settings. These factors may impact the quality and reliability of MRD assessment.

查看译文

关键词

leukemia,minimal/measurable residual disease,b-cell,bcp-all

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要